​
​

Verve Therapeutics (VERV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

VERV Stock Forecast

Verve Therapeutics stock forecast is as follows: an average price target of $19.00 (represents a 322.22% upside from VERV’s last price of $4.50) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.

VERV Price Target

The average price target for Verve Therapeutics (VERV) is $19.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $13.00. This represents a potential 322.22% upside from VERV's last price of $4.50.

VERV Analyst Ratings

Buy

According to 8 Wall Street analysts, Verve Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VERV stock is 0 'Strong Buy' (0.00%), 5 'Buy' (62.50%), 2 'Hold' (25.00%), 1 'Sell' (12.50%), and 0 'Strong Sell' (0.00%).

Verve Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 06, 2024Mitchell KapoorH.C. Wainwright$14.00$6.32121.69%211.11%
Apr 03, 2024Kostas BiliourisBMO Capital$30.00$8.57250.06%566.67%
Dec 15, 2022-Goldman Sachs$13.00$22.61-42.50%188.89%
Row per page
Go to

The latest Verve Therapeutics stock forecast, released on Nov 06, 2024 by Mitchell Kapoor from H.C. Wainwright, set a price target of $14.00, which represents a 121.69% increase from the stock price at the time of the forecast ($6.32), and a 211.11% increase from VERV last price ($4.50).

Verve Therapeutics Price Target by Period

1M3M12M
# Anlaysts112
Avg Price Target$14.00$14.00$22.00
Last Closing Price$4.50$4.50$4.50
Upside/Downside211.11%211.11%388.89%

In the current month, the average price target of Verve Therapeutics stock is $14.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 211.11% increase as opposed to Verve Therapeutics's last price of $4.50. This month's average price target is down 0.00% compared to last quarter, and down -36.36% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 06, 2024H.C. WainwrightBuyBuyHold
Aug 09, 2024RBC CapitalOutperformOutperformHold
May 09, 2024JefferiesBuyBuyHold
Apr 08, 2024H.C. Wainwright-BuyInitialise
Apr 03, 2024BMO CapitalOutperformOutperformHold
Apr 02, 2024RBC CapitalOutperformOutperformHold
Feb 01, 2023Cantor Fitzgerald-NeutralInitialise
Dec 15, 2022Goldman Sachs-SellInitialise
Oct 06, 2022Credit Suisse-NeutralInitialise
Aug 25, 2022Telsey Advisory-BuyUpgrade
Row per page
Go to

Verve Therapeutics's last stock rating was published by H.C. Wainwright on Nov 06, 2024. The company gave VERV a "Buy" rating, the same as its previous rate.

Verve Therapeutics Financial Forecast

Verve Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22
Revenue--------$5.14M$3.12M$2.09M$1.40M$1.01M$929.00K
Avg Forecast$3.72M$3.37M$2.97M$3.17M$3.57M$2.75M$2.40M$2.11M$3.77M$963.67K$672.67K$450.00K$730.29K$833.33K
High Forecast$3.94M$3.57M$3.15M$3.36M$3.96M$2.77M$2.40M$2.11M$4.31M$963.83K$712.26K$476.49K$773.27K$833.33K
Low Forecast$3.49M$3.17M$2.80M$2.98M$3.17M$2.72M$2.40M$2.11M$3.23M$963.50K$632.61K$423.20K$686.80K$833.33K
# Analysts11134244544433
Surprise %--------1.37%3.23%3.11%3.12%1.39%1.11%

Verve Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $2.11M, with a low forecast of $2.11M, and a high forecast of $2.11M. VERV's average Quarter revenue forecast represents a -59.02% decrease compared to the company's last Quarter revenue of $5.14M (Dec 23).

Verve Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22
# Analysts11134244544433
EBITDA--------$-52.43M$-52.33M$-58.58M$-58.26M$-46.78M$-43.86M
Avg Forecast$743.25K$674.60K$594.60K$634.60K$713.30K$549.23K$480.29K$421.63K$753.02K$192.73K$134.53K$90.00K$146.06K$166.67K
High Forecast$787.00K$714.31K$629.60K$671.95K$792.55K$554.24K$480.34K$421.64K$861.68K$192.77K$142.45K$95.30K$154.65K$166.67K
Low Forecast$698.99K$634.43K$559.19K$596.81K$633.12K$544.21K$480.25K$421.61K$646.26K$192.70K$126.52K$84.64K$137.36K$166.67K
Surprise %---------69.63%-271.54%-435.45%-647.33%-320.32%-263.16%

undefined analysts predict VERV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Verve Therapeutics's previous annual EBITDA (undefined) of $NaN.

Verve Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22
# Analysts11134244544433
Net Income--------$-48.35M$-45.76M$-53.98M$-45.69M$-41.09M$-46.52M
Avg Forecast$-63.53M$-64.59M$-63.10M$-62.06M$-57.88M$-57.86M$-57.32M$-59.37M$-63.83M$-76.57M$-77.71M$-65.07M$-60.99M$-62.48M
High Forecast$-58.61M$-59.59M$-58.22M$-52.45M$-44.83M$-53.38M$-52.88M$-54.78M$-55.85M$-70.64M$-71.70M$-60.04M$-56.27M$-62.48M
Low Forecast$-68.39M$-69.53M$-67.93M$-76.05M$-73.36M$-62.28M$-61.71M$-63.92M$-67.82M$-82.43M$-83.66M$-70.05M$-65.65M$-62.48M
Surprise %--------0.76%0.60%0.69%0.70%0.67%0.74%

Verve Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VERV's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Verve Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22
# Analysts11134244544433
SG&A--------$10.76M$11.69M$13.42M$12.55M$11.44M$9.59M
Avg Forecast$19.76M$17.93M$15.81M$16.87M$18.96M$14.60M$12.77M$11.21M$20.02M$5.12M$3.58M$2.39M$3.88M$4.35M
High Forecast$20.92M$18.99M$16.74M$17.86M$21.07M$14.73M$12.77M$11.21M$22.91M$5.12M$3.79M$2.53M$4.11M$4.35M
Low Forecast$18.58M$16.87M$14.87M$15.87M$16.83M$14.47M$12.77M$11.21M$17.18M$5.12M$3.36M$2.25M$3.65M$4.35M
Surprise %--------0.54%2.28%3.75%5.25%2.95%2.20%

Verve Therapeutics's average Quarter SG&A projection for Mar 24 is $11.21M, based on 4 Wall Street analysts, with a range of $11.21M to $11.21M. The forecast indicates a 4.13% rise compared to VERV last annual SG&A of $10.76M (Dec 23).

Verve Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22
# Analysts11134244544433
EPS--------$-0.69$-0.72$-0.87$-0.74$-0.67$-0.81
Avg Forecast$-0.75$-0.76$-0.75$-0.73$-0.68$-0.68$-0.68$-0.70$-0.75$-0.90$-0.92$-0.77$-0.72$-0.74
High Forecast$-0.69$-0.70$-0.69$-0.62$-0.53$-0.63$-0.62$-0.65$-0.66$-0.83$-0.85$-0.71$-0.66$-0.74
Low Forecast$-0.81$-0.82$-0.80$-0.90$-0.87$-0.74$-0.73$-0.76$-0.80$-0.97$-0.99$-0.83$-0.78$-0.74
Surprise %--------0.91%0.80%0.95%0.96%0.93%1.09%

According to undefined Wall Street analysts, Verve Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VERV previous annual EPS of $NaN (undefined).

Verve Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
IPSCCentury Therapeutics$1.25$15.001100.00%Buy
NTLAIntellia Therapeutics$14.17$115.90717.93%Buy
LIFEaTyr Pharma$1.90$11.00478.95%Buy
PRMEPrime Medicine$3.18$17.25442.45%Buy
EDITEditas Medicine$2.52$12.85409.92%Buy
VERVVerve Therapeutics$4.50$19.00322.22%Buy
RLAYRelay Therapeutics$4.89$19.40296.73%Buy
SANASana Bio$2.34$8.00241.88%Buy
ADPTAdaptive Bio$4.68$12.33163.46%Hold
BEAMBeam Therapeutics$24.12$58.50142.54%Buy
CRSPCRISPR Therapeutics$47.30$101.46114.50%Buy
CRBUCaribou Biosciences$1.98$3.0051.52%Buy
BPMCBlueprint Medicines$90.18$109.7121.66%Buy

VERV Forecast FAQ

Is Verve Therapeutics a good buy?

Yes, according to 8 Wall Street analysts, Verve Therapeutics (VERV) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 62.50% of VERV's total ratings.

What is VERV's price target?

Verve Therapeutics (VERV) average price target is $19 with a range of $13 to $30, implying a 322.22% from its last price of $4.5. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Verve Therapeutics stock go up soon?

According to Wall Street analysts' prediction for VERV stock, the company can go up by 322.22% (from the last price of $4.5 to the average price target of $19), up by 566.67% based on the highest stock price target, and up by 188.89% based on the lowest stock price target.

Can Verve Therapeutics stock reach $7?

VERV's average twelve months analyst stock price target of $19 supports the claim that Verve Therapeutics can reach $7 in the near future.

What is Verve Therapeutics's current price target trend?

1 Wall Street analyst forecast a $14 price target for Verve Therapeutics (VERV) this month, up 211.11% from its last price of $4.5. Compared to the last 3 and 12 months, the average price target increased by 211.11% and increased by 388.89%, respectively.

What are Verve Therapeutics's analysts' financial forecasts?

Verve Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $10.82M (high $11.24M, low $10.4M), average EBITDA is $2.16M (high $2.25M, low $2.08M), average net income is $-232M (high $-206M, low $-261M), average SG&A $57.54M (high $59.78M, low $55.27M), and average EPS is $-2.746 (high $-2.432, low $-3.087). VERV's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $13.24M (high $14.01M, low $12.45M), average EBITDA is $2.65M (high $2.8M, low $2.49M), average net income is $-253M (high $-229M, low $-282M), average SG&A $70.37M (high $74.51M, low $66.18M), and average EPS is $-2.993 (high $-2.704, low $-3.331).

Did the VERV's actual financial results beat the analysts' financial forecasts?

Based on Verve Therapeutics's last annual report (Dec 2023), the company's revenue was $11.76M, beating the average analysts forecast of $5.85M by 100.94%. Apple's EBITDA was $-218M, missing the average prediction of $1.17M by -18699.63%. The company's net income was $-200M, missing the average estimation of $-283M by -29.35%. Apple's SG&A was $44.48M, beating the average forecast of $31.11M by 42.98%. Lastly, the company's EPS was $-3.12, missing the average prediction of $-3.346 by -6.76%. In terms of the last quarterly report (Dec 2023), Verve Therapeutics's revenue was $5.14M, beating the average analysts' forecast of $3.77M by 36.62%. The company's EBITDA was $-52.431M, missing the average prediction of $753.02K by -7062.74%. Verve Therapeutics's net income was $-48.352M, missing the average estimation of $-63.83M by -24.25%. The company's SG&A was $10.76M, missing the average forecast of $20.02M by -46.23%. Lastly, the company's EPS was $-0.69, missing the average prediction of $-0.754 by -8.51%